Picture of Vitrolife AB logo

VITR — Vitrolife AB News Story

0.000.00%
se flag iconLast trade - 00:00
HealthcareSpeculativeMid CapMomentum Trap

Sweden's Vitrolife flags $409 mln impairment charge in Q4 (updated)

(Adds background in paragraphs 3, results in paragraph 4)
       Jan 23 (Reuters) - Swedish medical technology group
Vitrolife  VITR.ST  said on Tuesday it will record a non-cash
impairment charge of 4.3 billion Swedish crowns ($409.44
million) in the fourth quarter, relating to its acquisition of
Igenomix.
    The impairment charge represents 31% of the accounted
goodwill and intangible assets tied to the deal.
    Vitrolife had bought reproductive genetic testing services
provider Igenomix in a deal worth 1.25 billion euros ($1.35
billion) in 2021.
    Vitrolife's preliminary fourth-quarter sales rose 5.7% to
904 million Swedish crowns, while its earnings before interest,
tax, depreciation and amortization (EBITDA) increased more than
7% to 294 million Swedish crowns.
    
    

($1 = 10.5021 Swedish crowns)


($1 = 0.9228 euros)

 (Reporting by Utkarsh Shetti in Bengaluru; Editing by Shilpi
Majumdar)
 ((UtkarshUmesh.Shetti@thomsonreuters.com;))

Recent news on Vitrolife AB

See all news